Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
J. C. Patterson, A. Varkaris, P. J. P. Croucher, M. Ridinger, S. Darlymple, M. Nouri, F. Xie, S. Varmeh, O. Jonas, M. A. Whitman, S. Chen, S. Rashed, L. Makusha, J. Luo, J. T. Isaacs, , M. B. Yaffe
This study shows that combining Plk1 inhibitors with abiraterone synergistically kills cancer cells across tumor types, independent of androgen receptor signaling, through mitotic disruption.
bioRxiv · May 12, 2022 · PreprintCancer Biology